21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: Results from NSABP B-28/NRG Oncology

BACKGROUND: The 21-gene Recurrence Score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene Recurrence Score (RS) for its prognostic impact and its ability to predic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Mamounas, Eleftherios P., Tang, Gong, Paik, Soonmyung, Baehner, Frederick L., Liu, Qing, Jeong, Jong-Hyeon, Kim, Seong-Rim, Butler, Steven M., Jamshidian, Farid, Cherbavaz, Diana B., Sing, Amy P., Shak, Steven, Julian, Thomas B., Lembersky, Barry C., Wickerham, D. Lawrence, Costantino, Joseph P., Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5996978/
https://ncbi.nlm.nih.gov/pubmed/29128898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4550-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados